Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.35
-$0.44-55.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -4.14% | -19.16% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.68% | -33.64% | |||
| Operating Income | 11.68% | 33.64% | |||
| Income Before Tax | 16.05% | 33.71% | |||
| Income Tax Expenses | 3.57% | -65.00% | |||
| Earnings from Continuing Operations | 16.03% | 33.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 16.03% | 33.75% | |||
| EBIT | 11.68% | 33.64% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 48.62% | 54.56% | |||
| Normalized Basic EPS | 48.63% | 54.53% | |||
| EPS Diluted | 48.62% | 54.56% | |||
| Normalized Diluted EPS | 48.63% | 54.53% | |||
| Average Basic Shares Outstanding | 63.43% | 45.82% | |||
| Average Diluted Shares Outstanding | 63.43% | 45.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||